Siponimod Patent Expiration
Siponimod is Used for treating multiple sclerosis. It was first introduced by Novartis Pharmaceuticals Corp
Siponimod Patents
Given below is the list of patents protecting Siponimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mayzent | US11944602 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | Jul 24, 2036 | Novartis |
| Mayzent | US12071402 | Immunosuppressant formulations | Jan 05, 2032 | Novartis |
| Mayzent | US8492441 | Dosage regimen of an S1P receptor agonist | Nov 30, 2030 | Novartis |
| Mayzent | US7939519 | Immunosuppresant compounds and compositions | Aug 27, 2028 | Novartis |
Siponimod's Family Patents
Explore Our Curated Drug Screens
Siponimod Generic API Manufacturers
Several generic applications have been filed for Siponimod.
Given below is the list of companies who have filed for Siponimod generic, along with the locations of their manufacturing plants worldwide.
1. RICONPHARMA LLC
Riconpharma Llc has filed for 3 different strengths of generic version for Siponimod. Given below are the details of the strengths of this generic introduced by Riconpharma Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE | tablet | Prescription | ORAL | AB | Apr 22, 2025 |
| EQ 1MG BASE | tablet | Prescription | ORAL | AB | Apr 22, 2025 |
| EQ 2MG BASE | tablet | Prescription | ORAL | AB | Apr 22, 2025 |
Manufacturing Plant Locations New
Riconpharma Llc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Riconpharma Llc as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||